Review



anti mers cov s2 antibody  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Sino Biological anti mers cov s2 antibody
    Anti Mers Cov S2 Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mers cov s2 antibody/product/Sino Biological
    Average 94 stars, based on 6 article reviews
    anti mers cov s2 antibody - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    anti mers cov s2 antibody  (Sino Biological)
    94
    Sino Biological anti mers cov s2 antibody
    Anti Mers Cov S2 Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mers cov s2 antibody/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    anti mers cov s2 antibody - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    baculovirus insect cells  (Sino Biological)
    97
    Sino Biological baculovirus insect cells
    Baculovirus Insect Cells, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baculovirus insect cells/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    baculovirus insect cells - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    hek293 cells  (Sino Biological)
    94
    Sino Biological hek293 cells
    Hek293 Cells, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hek293 cells/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    hek293 cells - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    recombinant sars cov  (Sino Biological)
    95
    Sino Biological recombinant sars cov
    Spike-specific immune <t>responses</t> <t>following</t> <t>SARS-CoV-2</t> vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.
    Recombinant Sars Cov, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant sars cov/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    recombinant sars cov - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    ancestral sars cov 2  (Sino Biological)
    95
    Sino Biological ancestral sars cov 2
    Spike-specific immune <t>responses</t> <t>following</t> <t>SARS-CoV-2</t> vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.
    Ancestral Sars Cov 2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ancestral sars cov 2/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    ancestral sars cov 2 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    sars cov 2 spike s1 s2 ecd  (Sino Biological)
    95
    Sino Biological sars cov 2 spike s1 s2 ecd
    Spike-specific immune <t>responses</t> <t>following</t> <t>SARS-CoV-2</t> vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.
    Sars Cov 2 Spike S1 S2 Ecd, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 spike s1 s2 ecd/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    sars cov 2 spike s1 s2 ecd - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    spike s1 s2 trimer wild type  (Sino Biological)
    95
    Sino Biological spike s1 s2 trimer wild type
    Spike-specific immune <t>responses</t> <t>following</t> <t>SARS-CoV-2</t> vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.
    Spike S1 S2 Trimer Wild Type, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/spike s1 s2 trimer wild type/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    spike s1 s2 trimer wild type - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    sars cov 2 spike protein 40589 v08h4  (Sino Biological)
    96
    Sino Biological sars cov 2 spike protein 40589 v08h4
    Germinal center responses to P20-H5 and bolus vaccines. a) Mice were immunized with vaccines at week 0 and draining lymph nodes were excised for flow cytometry analysis at week 3. b,c) Count of (b) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (c) T FH cells (CD45 + CD11b − CD19 − CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization <t>with</t> <t>WT</t> <t>SARS-CoV-2</t> vaccine (n = 7). d, e) Count of (d) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (e) T FH cells (CD45 + CD11b − CD19 − , CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with H5N1 influenza vaccines (n = 7)
    Sars Cov 2 Spike Protein 40589 V08h4, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 spike protein 40589 v08h4/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    sars cov 2 spike protein 40589 v08h4 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    baculovirus  (Sino Biological)
    97
    Sino Biological baculovirus
    Germinal center responses to P20-H5 and bolus vaccines. a) Mice were immunized with vaccines at week 0 and draining lymph nodes were excised for flow cytometry analysis at week 3. b,c) Count of (b) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (c) T FH cells (CD45 + CD11b − CD19 − CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization <t>with</t> <t>WT</t> <t>SARS-CoV-2</t> vaccine (n = 7). d, e) Count of (d) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (e) T FH cells (CD45 + CD11b − CD19 − , CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with H5N1 influenza vaccines (n = 7)
    Baculovirus, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baculovirus/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    baculovirus - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Spike-specific immune responses following SARS-CoV-2 vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.

    Journal: Human Vaccines & Immunotherapeutics

    Article Title: Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome

    doi: 10.1080/21645515.2026.2612817

    Figure Lengend Snippet: Spike-specific immune responses following SARS-CoV-2 vaccination in RTT and HC. (A) Longitudinal spike-specific IgG analysis from baseline (0) to 6 months post third dose (day 450) in HC with overlaid single values assessed in RTT patients. The first (v1, day 0), second (v2, day21) and third (v3, day270) vaccine dose administration is shown by arrows. (B) Spike-specific IgG titres (GMT with range) detected in RTT patients vaccinated with two (v2) or three (v3) doses, with (+) or without (–) SARS-CoV-2 infection. (C) ACE2/RBD binding inhibition assay. The dotted line at 30% inhibition percentage, indicates the threshold of positivity of the assay. (D) RBD + MBCs gating strategy and (E) frequencies of RBD + MBC in RTT and HC following two and three vaccine doses in SARS-CoV-2 infected (filled symbols) or non-infected (open symbols) individuals. (F) FlowSOM clustering analysis performed on total MBCs (left heatmap), and RBD + MBCs (right heatmap). (G) Spike-specific IgG-secreting MBCs assessed by ELISpot assay and (H) their frequencies in RTT and HC. Data from SARS-CoV-2 infected individuals are shown as filled symbols. Statistical differences were assessed by Mann–Whitney test.

    Article Snippet: Recombinant SARS-CoV-2 full Spike protein (Sino Biological; 1 ug/ml protein) was used for coating wells in ELISA assay.

    Techniques: Infection, Binding Assay, Inhibition, Enzyme-linked Immunospot, MANN-WHITNEY

    Germinal center responses to P20-H5 and bolus vaccines. a) Mice were immunized with vaccines at week 0 and draining lymph nodes were excised for flow cytometry analysis at week 3. b,c) Count of (b) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (c) T FH cells (CD45 + CD11b − CD19 − CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with WT SARS-CoV-2 vaccine (n = 7). d, e) Count of (d) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (e) T FH cells (CD45 + CD11b − CD19 − , CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with H5N1 influenza vaccines (n = 7)

    Journal: Biomaterials science

    Article Title: Enabling Global Access to Potent Subunit Vaccines with a Simple and Scalable Injectable Hydrogel Platform

    doi: 10.1039/d5bm01131k

    Figure Lengend Snippet: Germinal center responses to P20-H5 and bolus vaccines. a) Mice were immunized with vaccines at week 0 and draining lymph nodes were excised for flow cytometry analysis at week 3. b,c) Count of (b) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (c) T FH cells (CD45 + CD11b − CD19 − CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with WT SARS-CoV-2 vaccine (n = 7). d, e) Count of (d) GCBCs (CD45 + CD11b − CD19 + CD95 + CD38 − ) or (e) T FH cells (CD45 + CD11b − CD19 − , CD3 + CD4 + CXCR5 + PD-1 + FOXP3 − Bcl6 + ) in dLNs three weeks post-prime immunization with H5N1 influenza vaccines (n = 7)

    Article Snippet: Influenza A H5N1 (A/Indonesia/5/2005) Hemagglutinin / HA Protein (His Tag) (H5N1-HA) and SARS-CoV-2 spike protein (40589-V08H4) (spike protein) were purchased from Sino Biological.

    Techniques: Vaccines, Flow Cytometry